清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy

医学 乳腺癌 内科学 肿瘤科 荟萃分析 优势比 激素受体 逻辑回归 化疗 癌症
作者
Nehmat Houssami,Petra Macaskill,Gϋnter von Minckwitz,M. Luke Marinovich,Eleftherios P. Mamounas
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:48 (18): 3342-3354 被引量:466
标识
DOI:10.1016/j.ejca.2012.05.023
摘要

BackgroundPathologic complete response (pCR) is a surrogate end-point for prognosis in neoadjuvant chemotherapy (NAC) for breast cancer. We aimed to report summary estimates of the proportion of subjects achieving pCR (pCR%) by tumour subtype, and to determine whether subtype was independently associated with pCR, in a study-level meta-analysis.MethodsWe systematically identified NAC studies reporting pCR data according to tumour subtype, using predefined eligibility criteria. Descriptive, qualitative and quantitative data were extracted. Random effects logistic meta-regression examined whether pCR% was associated with subtype, defined using three categories for model 1 [hormone receptor positive (HR+/HER2–), HER2 positive (HER2+), triple negative (ER–/PR–/HER2–)] and 4 categories for model 2 [HER2+ further classified as HER2+/HR+ and HER2+/HR–]. Subtype-specific odds ratios (OR) were calculated and were adjusted for covariates associated with pCR in our data.ResultsIn model 1, based on 11,695 subjects from 30 eligible studies, overall pooled pCR% was 18.9% (16.6–21.5%), and in model 2 (20 studies, 8095 subjects) pooled pCR% was 18.5% (16.2-21.1%); tumour subtype was associated with pCR% (P < 0.0001) in both models. Subtype-specific pCR% (model 2) was: 8.3% (6.7–10.2%) in HR+/HER2– [OR 1/referent], 18.7% (15.0–23.1%) in HER2+/HR+ [OR 2.6], 38.9% (33.2–44.9%) in HER2+/HR– [OR 7.1] and 31.1% (26.5–36.1%) in triple negative [OR 5.0]; pCR% was significantly higher for the HER2+/HR– compared with the triple negative subtype, however pCR% was very similar for these subtypes (and OR = 5.0 both subtypes) when studies using HER2-directed therapy with NAC were excluded from the model. Neither sensitivity analysis (excluding unknown subtypes), nor adjustment for associated covariates, substantially altered our findings.InterpretationThis meta-analysis provides evidence of an independent association between breast cancer subtype and pCR; odds of pCR were highest for the triple negative and HER2+/HR– subtypes, with evidence of an influential effect on achieving pCR in the latter subtype through inclusion of HER2-directed therapy with NAC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhao完成签到,获得积分10
4秒前
Hua完成签到,获得积分0
19秒前
dingding完成签到,获得积分10
21秒前
月儿完成签到 ,获得积分10
24秒前
科研通AI2S应助科研通管家采纳,获得10
30秒前
YifanWang应助科研通管家采纳,获得10
30秒前
YifanWang应助科研通管家采纳,获得10
30秒前
YifanWang应助科研通管家采纳,获得40
30秒前
蔡从安发布了新的文献求助10
32秒前
糖醋里脊加醋完成签到 ,获得积分10
34秒前
欢喜白亦完成签到 ,获得积分10
35秒前
KINGAZX完成签到 ,获得积分10
48秒前
luckyalias完成签到 ,获得积分10
56秒前
zhangsan完成签到,获得积分10
1分钟前
1分钟前
雪白小丸子完成签到,获得积分10
1分钟前
www发布了新的文献求助30
1分钟前
蔡从安发布了新的文献求助10
1分钟前
脑洞疼应助蔡从安采纳,获得10
1分钟前
1分钟前
彩色的芷容完成签到 ,获得积分10
1分钟前
东郭凝蝶完成签到 ,获得积分10
2分钟前
宇文非笑完成签到 ,获得积分0
2分钟前
2分钟前
玛卡巴卡爱吃饭完成签到 ,获得积分10
3分钟前
3分钟前
apckkk完成签到 ,获得积分10
4分钟前
4分钟前
YifanWang应助科研通管家采纳,获得20
4分钟前
YifanWang应助科研通管家采纳,获得10
4分钟前
YifanWang应助科研通管家采纳,获得20
4分钟前
默默雪旋完成签到 ,获得积分10
4分钟前
坚强的铅笔完成签到 ,获得积分10
4分钟前
wdy111应助wbh采纳,获得20
4分钟前
无限晓蓝完成签到 ,获得积分10
4分钟前
4分钟前
5分钟前
ceeray23发布了新的文献求助20
5分钟前
XIA完成签到 ,获得积分10
5分钟前
喜悦的香之完成签到 ,获得积分10
5分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990603
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256532
捐赠科研通 3271057
什么是DOI,文献DOI怎么找? 1805229
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234